Clinical trials: Decompensated Liver Cirrhosis
Hemostasis in Decompensated Liver Cirrhosis, Inflammation in Decompensated Liver Cirrhosis
Hemostasis in Liver Cirrhosis and Hepatocellular Cancer
Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.
- Trial name
- HELICS (NCT06212635)
- Testing
- T-TAS
- Where
- Sweden
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Region Stockholm
Liver Cirrhosis, Decompensated Cirrhosis of Liver
Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis
The study aims to test the effectiveness of new biomarkers (measurable molecules in our body) in predicting the health outcome of patients with liver cirrhosis discharged from the hospital after a serious complication of the…
- Trial name
- PROSPECT (NCT06855056)
- Where
- 9 sites in France, Germany and 3 more
- Volunteers
- 189 people
- Sponsor
- European Foundation for Study of Chronic Liver Failure
Cirrhosis
Study Of Bacterial/Fungal Infections in Hospitalized Patients With Liver Cirrhosis in China
This is a national, investigator-initiated, multicenter, prospective, observational, web-based registry in hospitalized patients with cirrhosis across China.
- Trial name
- SONIC (NCT03676777)
- Where
- 23 sites in China
- Volunteers
- 1,232 people
- Sponsor
- Ruijin Hospital
Decompensated Cirrhosis
Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis
This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of emricasan in improving event-free survival based on a composite clinical endpoint (where all-cause mortality, new…
- Trial name
- ENCORE-LF (NCT03205345)
- Testing
- Emricasan (25 mg), Emricasan (5 mg)
- Where
- 76 sites in United States
- Volunteers
- 210 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Decompensated Cirrhosis, Cirrhotic Cardiomyopathy
Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival
Cirrhosis and portal hypertension are associated with a hyperdynamic circulation and decompensation events, including development of ascites, variceal bleeding, acute kidney injury, and susceptibility to infections.
- Conditions
- Decompensated Cirrhosis, Cirrhotic Cardiomyopathy, Cirrhosis, Liver, Left Ventricular Diastolic Dysfunction
- Trial name
- CIRROSTAT (NCT06431919)
- Testing
- Simvastatin 20mg, Carvedilol 3.125 mg
- Where
- India
- Volunteers
- 260 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Liver Cirrhosis
Muscle Tissue Oxygenation in Patients With Decompensated Liver Cirrhosis
Patients with decompensated liver cirrhosis exhibit numerous hemodynamic and microvascular changes, i.e., low systemic blood pressure and peripheral vasodilatation.
- Trial name
- NCT00849641
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- University of Regensburg
Cirrhosis, Decompensated Cirrhosis of Liver
Effect of Non-Selective Beta-Blockers on Outcomes in Cirrhosis Patients After Hospitalization: A Retrospective Cohort Using Target Trial Design
The goal of this observational study is to learn if non-selective beta-blockers (NSBB) improve outcomes in patients with chronic hepatitis B or C who are discharged after hospitalization for acute decompensation of cirrhosis.
- Trial name
- NCT06977685
- Testing
- Non-selective beta-blockers
- Where
- South Korea
- Volunteers
- 7,725 people
- Sponsor
- Samsung Medical Center
Decompensated Cirrhosis, Severe Ascites
Efficacy of Combination of Midodrine With Propranolol in Preventing First Bleed in Decompensated Cirrhotics With Severe Ascites.
Study population: Decompensated cirrhotics requiring primary prophylaxis with asciteswho are admitted to and attending the OPD at ILBS.
- Trial name
- NCT04208776
- Testing
- Propranolol, Midodrine
- Where
- India
- Volunteers
- 140 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
End-stage Liver Disease (ESLD), Cirrhosis, Liver
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
The purpose of this study is to assess the safety and efficacy of RTX001 in patients with end-stage liver disease. This study is the first time RTX001, a macrophage cell therapy engineered to have an anti-inflammatory and…
- Conditions
- End-stage Liver Disease (ESLD), Cirrhosis, Liver, Cirrhosis, Decompensated, Liver Diseases
- Trial name
- EMERALD (NCT06823713)
- Testing
- RTX001
- Where
- 15 sites in Spain, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Resolution Therapeutics Limited
Decompensated Cirrhosis
Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis
It is still not clear whether rifaximin can prevent the progression of liver cirrhosis, reduce the overall complications and improve the survival in patients with decompensated cirrhosis.
- Trial name
- RPPCLC (NCT05863364)
- Testing
- Low-dose of Rifaximin, Conventional dose of Rifaximin
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Xin Zeng
Cirrhosis, Liver
Combination of Autologous MSC and HSC Infusion in Patients With Decompensated Cirrhosis
Though the results of autologous CD34+ cell infusion and MSC in independent studies have shown promise, yet they are yet to reach the desired long term outcome.
- Trial name
- NCT04243681
- Testing
- CD 34 and MSC infusion, Standard of care for Cirrhosis management
- Where
- India
- Volunteers
- 5 people
- Sponsor
- Asian Institute of Gastroenterology, India
Hepatitis B
hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis
1. Evaluation the safety of using human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis. 2. Observe the curative effect of patients with hepatitis B cirrhosis who use human umbilical mesenchymal stem…
- Trial name
- NCT03826433
- Testing
- Peripheral iv
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Exocrine Pancreatic Insufficiency
Prevalence of Exocrine Pancreatic Insufficiency in Patients With Decompensated Cirrhosis
Exocrine pancreatic insufficiency (EPI) is the inability of the pancreas to perform a normal digestive function. The prevalence of IPE in patients with decompensated hepatic cirrhosis (HC) is unknown and most published series are…
- Trial name
- (EPIIHC) (NCT03236038)
- Testing
- Labeled triolein urea breath test
- Where
- Spain
- Volunteers
- 125 people
- Sponsor
- Corporacion Parc Tauli
Decompensated Cirrhosis and Ascites
Oral Branched-chain Amino Acid Supplementation for Decompensated Cirrhotic Patients
The goal of this clinical trial is to compare the nutritional parameters after 12-week supplementation of branched-chain amino acids in cirrhotic patients with ascites and serum albumin less than 3 g/dL.
- Trial name
- NCT06121479
- Testing
- Branched-chain amino acid
- Where
- Thailand
- Volunteers
- 30 people
- Sponsor
- Mahidol University
Decompensated Cirrhosis
Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis
Decompensated cirrhosis has a high overall mortality rate. There is a large unmet need for safe and alternative therapeutic potions.
- Trial name
- NCT05121870
- Testing
- UC-MSCs, Saline containing 1% Human serum albumin（solution without UC-MSCs）
- Where
- 5 sites in China
- Volunteers
- 240 people
- Sponsor
- Beijing 302 Hospital
Liver Cirrhoses
Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development
The aim of this study is to assess the efficacy of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis to halt the progression of the disease as assessed by prevention of the development of…
- Trial name
- 2018-001698-25 (NCT03780673)
- Testing
- Simvastatin, Rifaximin
- Where
- 14 sites in Belgium, France and 5 more
- Volunteers
- 254 people
- Sponsor
- Judit Pich
Chronic Hepatitis C
A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C
The primary objective of this program is to provide DCV for 24 weeks to be given in combination with SOF to subjects with chronic hepatitis C with decompensated cirrhosis or post-liver transplant subjects with chronic hepatitis C…
- Trial name
- NCT02161939
- Testing
- Daclatasvir (BMS-790052), Sofosbuvir
- Where
- 20 sites in United States
- Sponsor
- Bristol-Myers Squibb
HBV
Clinical Study of hUC-MSCs Treating Decompensated Liver Cirrhosis With HBV
The purpose of this study was to observe the safety ,tolerability ,Efficacy dose of human umbilical cord mesenchymal stem cells in patients of decompensated liver cirrhosis with HBV.
- Trial name
- CS-hUC-MSCs (NCT05442437)
- Testing
- hUCMSCs
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Zhongnan Hospital
Decompensated Cirrhosis
A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HCL001 Cell Injection (Homologous Allogeneic Hepatocytes) in Patients With Decompensated Cirrhosis
This study protocol is designed to evaluate the clinical efficacy, safety, and tolerability of HCL001 cell injection in the treatment of decompensated cirrhosis.
- Trial name
- NCT06306781
- Testing
- HCL001 cell (homologous allogeneic hepatocytes) injection
- Volunteers
- 18 people
- Sponsor
- RenJi Hospital
Cirrhosis, Liver
G-CSF in Decompensated Cirrhosis: an Open Label Trial
Globally, cirrhosis is the fifth commonest cause of mortality. Its natural history is typified by an initial, largely asymptomatic, "compensated" phase followed by "decompensation" due to complications of raised portal pressures…
- Trial name
- NCT03415698
- Testing
- G-CSF, Standard Medical Therapy
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh